Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs

被引：0
|
作者：
Kenneth W. Sommerville
Sandeep Dutta
Victor Biton
Yiming Zhang
James C. Cloyd
Basim Uthman
机构：
[1] Abbott Laboratories,
[2] Arkansas Epilepsy Program,undefined
[3] University of Minnesota College of Pharmacy,undefined
[4] Malcolm Randall VAMC Neurology Service and University of Florida,undefined
[5] Department R-4PK,undefined
来源：
Clinical Drug Investigation | 2003年 / 23卷
关键词：
Lamotrigine; Topiramate; Oxcarbazepine; Relative Bioavailability; Primidone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：661 / 670
页数：9
相关论文
共 24 条
  • [1] Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs
    Sommerville, KW
    Dutta, S
    Biton, V
    Zhang, YM
    Cloyd, JC
    Uthman, B
    CLINICAL DRUG INVESTIGATION, 2003, 23 (10) : 661 - 670
  • [2] Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation
    Dutta, S
    Zhang, YM
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2004, 25 (08) : 345 - 352
  • [3] Comparison of the bioavailability of unequal doses of Depakote extended-release (ER) formulation relative to Depakote delayed-release (DR) formulation in epilepsy patients on concomitant enzyme-inducing antiepileptic drugs (EIAED)
    Dutta, S
    Sommerville, KW
    Zhang, YM
    Lamm, J
    Lee, LL
    Owen, JR
    Biton, V
    Combs-Cantrell, DT
    Krishnamurthy, B
    Cloyd, JC
    Uthman, BM
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1064 - 1064
  • [4] Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers
    Dutta, S
    Zhang, YM
    Selness, DS
    Lee, LL
    Williams, LA
    Sommerville, KW
    EPILEPSY RESEARCH, 2002, 49 (01) : 1 - 10
  • [5] Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium
    Horne, RL
    Cunanan, C
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) : 176 - 181
  • [6] Bone density in patients receiving enzyme-inducing antiepileptic drugs
    Pack, AM
    Olarte, LS
    Flaster, E
    Resor, SR
    NEUROLOGY, 2002, 58 (07) : A175 - A175
  • [7] Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials
    Zhang, Chen Qi
    Li, Hong Yan
    Wan, Yong
    Bai, Xue Yang
    Gan, Lu
    Wang, Juan
    Sun, Hong Bin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex A protocol for systematic review and meta-analysis
    Zhang, Chen Qi
    Bai, Xue Yang
    Wan, Yong
    Li, Hong Yan
    Sun, Hongbin
    MEDICINE, 2021, 100 (50) : E28290
  • [9] ABSOLUTE BIOAVAILABILITY OF DIVALPROEX SODIUM EXTENDED-RELEASE IN ELDERLY PATIENTS WITH EPILEPSY BY A STABLE ISOTOPE TECHNIQUE
    Ramsay, R. E.
    Reed, R.
    Marino, S.
    Rarick, J.
    Leppik, I
    Birnbaum, A.
    Remmel, R. P.
    EPILEPSIA, 2010, 51 : 95 - 95
  • [10] ABSOLUTE BIOAVAILABILITY OF DIVALPROEX SODIUM EXTENDED-RELEASE IN ELDERLY PATIENTS WITH EPILEPSY BY A STABLE ISOTOPE TECHNIQUE
    Remmel, Rory
    Marino, S. E.
    Reed, R. C.
    Conway, J. M.
    Rarick, J. O.
    Birnbaum, A. K.
    Leppik, I. E.
    Llorente, M.
    Preston, R.
    Segura, R.
    Ramsay, R. E.
    EPILEPSIA, 2009, 50 : 117 - 117
123